医学
重症监护医学
临床试验
动脉粥样硬化性心血管疾病
疾病
风险分析(工程)
相(物质)
冠心病
心力衰竭
梅德林
作者
Kunal Sharma,Lakshmi Kattamuri,Debabrata Mukherjee
出处
期刊:Cardiovascular and Hematological Disorders - Drug Targets
[Bentham Science Publishers]
日期:2025-10-14
卷期号:25
标识
DOI:10.2174/011871529x399029250923100015
摘要
Pelacarsen (TQJ230) is a potent Lp(a)-lowering agent with promising efficacy and a favorable safety profile. However, its definitive role in reducing atherosclerotic cardiovascular events remains to be established. Ongoing Phase 3 trials will be critical in determining whether its lipid-lowering effects translate into meaningful long-term cardiovascular outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI